Objective： To investigate the recurrence sites, risk factors, and prognosis of＇patients with persistent or recurrent squamous cell carcinoma （SCC） of the cervix within one year after undergoing concurrent chemorad...Objective： To investigate the recurrence sites, risk factors, and prognosis of＇patients with persistent or recurrent squamous cell carcinoma （SCC） of the cervix within one year after undergoing concurrent chemoradiotherapy （CCRT）. Methods： Clinical data of 30 patients with persistent or recurrent SCC of the cervix within one year after CCRT between July 2006 and July 2011 were analyzed retrospectively： These data were compared with those of 35 SCC cases with no signs of recurrence after complete remission. These 35 patients were treated during the same period （between 2,006 and Z011） and selected randomly. Results： Among these 30 patients, 25 exhibited distant metastases of which 14 were observed within 6 months after CCRT. Univariate analysis showed higher incidence of pelvic or para-aortic lymphadenectasis and SCC-ag 〉 10 ng/mL in the group with persistent or recurrent disease before treatment （P〈0.01）. Multivariate analysis by logistic regression revealed that the pre-therapeutic pelvic or para-aortic lymph node enlargement and SCC-ag 〉 10 ng/mL were the independent risk factors. Palliative chemotherapy was the main treatment option for patients with persistent or recurrent disease. The 2-year survival rate was 21.7%, and the median survival time was 17 months. Conclusion： Patients with persistent or recurrent SCC of the cervix after CCRT exhibited a high rate of distant metastasis with poor prognosis. The pre-therapeutic pelvic or para-aortic lymph node enlargement and SCC-ag 〉10 ng/mL were identified as the independent risk factors for persistent or recurrent SCC within i year after CCRT.展开更多
目的:探讨宫颈癌p53、c-erbB-2蛋白的表达及临床意义。方法:采用免疫组织化学E liV ision二步法检测43例宫颈癌组织切片的p53、c-erbB-2蛋白表达,并结合临床病理资料进行分析。结果:(1)p53、c-erbB-2蛋白阳性表达率分别为74.4%和69.8%;(...目的:探讨宫颈癌p53、c-erbB-2蛋白的表达及临床意义。方法:采用免疫组织化学E liV ision二步法检测43例宫颈癌组织切片的p53、c-erbB-2蛋白表达,并结合临床病理资料进行分析。结果:(1)p53、c-erbB-2蛋白阳性表达率分别为74.4%和69.8%;(2)p53蛋白的表达在鳞癌高于腺癌(P<0.05),其表达与年龄、临床分期、临床分型、病理分级、宫旁浸润、近期疗效无明显相关(P>0.05);(3)c-erbB-2蛋白的表达在鳞癌的病理分级、宫旁浸润中有显著差异(P<0.01),在临床分期的表达中也有显著差异(P<0.05),但与年龄、临床分型、近期疗效、病理类型、腺癌的病理分级无明显相关(P>0.05);(4)p53与c-erbB-2蛋白共同阳性表达在癌旁浸润中,有显著差异(P<0.01),二者阳性表达随宫颈癌临床分期表达增高(P<0.05)。结论:c-erbB-2蛋白阳性表达与宫颈癌恶性程度呈正相关;p53与c-erbB-2蛋白共同阳性表达与癌旁浸润有关,随临床分期表达增高,提示宫颈癌的发生发展可能有多种癌基因共同参与。展开更多
文摘Objective： To investigate the recurrence sites, risk factors, and prognosis of＇patients with persistent or recurrent squamous cell carcinoma （SCC） of the cervix within one year after undergoing concurrent chemoradiotherapy （CCRT）. Methods： Clinical data of 30 patients with persistent or recurrent SCC of the cervix within one year after CCRT between July 2006 and July 2011 were analyzed retrospectively： These data were compared with those of 35 SCC cases with no signs of recurrence after complete remission. These 35 patients were treated during the same period （between 2,006 and Z011） and selected randomly. Results： Among these 30 patients, 25 exhibited distant metastases of which 14 were observed within 6 months after CCRT. Univariate analysis showed higher incidence of pelvic or para-aortic lymphadenectasis and SCC-ag 〉 10 ng/mL in the group with persistent or recurrent disease before treatment （P〈0.01）. Multivariate analysis by logistic regression revealed that the pre-therapeutic pelvic or para-aortic lymph node enlargement and SCC-ag 〉 10 ng/mL were the independent risk factors. Palliative chemotherapy was the main treatment option for patients with persistent or recurrent disease. The 2-year survival rate was 21.7%, and the median survival time was 17 months. Conclusion： Patients with persistent or recurrent SCC of the cervix after CCRT exhibited a high rate of distant metastasis with poor prognosis. The pre-therapeutic pelvic or para-aortic lymph node enlargement and SCC-ag 〉10 ng/mL were identified as the independent risk factors for persistent or recurrent SCC within i year after CCRT.
文摘目的:探讨宫颈癌p53、c-erbB-2蛋白的表达及临床意义。方法:采用免疫组织化学E liV ision二步法检测43例宫颈癌组织切片的p53、c-erbB-2蛋白表达,并结合临床病理资料进行分析。结果:(1)p53、c-erbB-2蛋白阳性表达率分别为74.4%和69.8%;(2)p53蛋白的表达在鳞癌高于腺癌(P<0.05),其表达与年龄、临床分期、临床分型、病理分级、宫旁浸润、近期疗效无明显相关(P>0.05);(3)c-erbB-2蛋白的表达在鳞癌的病理分级、宫旁浸润中有显著差异(P<0.01),在临床分期的表达中也有显著差异(P<0.05),但与年龄、临床分型、近期疗效、病理类型、腺癌的病理分级无明显相关(P>0.05);(4)p53与c-erbB-2蛋白共同阳性表达在癌旁浸润中,有显著差异(P<0.01),二者阳性表达随宫颈癌临床分期表达增高(P<0.05)。结论:c-erbB-2蛋白阳性表达与宫颈癌恶性程度呈正相关;p53与c-erbB-2蛋白共同阳性表达与癌旁浸润有关,随临床分期表达增高,提示宫颈癌的发生发展可能有多种癌基因共同参与。
